title: Lack of oral kallikrein in lowering systemic blood pressure in primary hypertension.
abstract: Primary hypertension is associated with a lack in renal kallikrein activity which might be one of the reasons for the blood pressure elevation. Some smaller and partially uncontrolled studies suggested that an oral substitution of glandular kallikrein lowers blood pressure by a kinin-mediated vasodilation and increased natriuresis. To test this hypothesis we treated in two studies over 100 patients with untreated mild to moderate primary hypertension (WHO I-II) for 5 resp. 12 weeks in a double blind randomized and placebo controlled manner with 1800 U glandular kallikrein orally. Blood pressure measurements were performed according to the two study designs after 3 and 5 resp. 8 and 12 weeks of treatment sphymomanometrically in the day time course. No significant changes in blood pressure by kallikrein treatment could be observed at any time. Neither renal kallikrein excretion, renin and ACE-activity nor blood glucose concentration in diabetics or non-diabetics was changed. Thus, we could undoubtedly demonstrate that oral applied glandular kallikrein has no effect on primary hypertension.
authors.affiliation: Department of Internal Medicine II, University of Cologne, Merheim Hospital, Köln, F.R.G.
authors.forename: G
authors.initials: G
authors.lastname: Bönner
authors.forename: C
authors.initials: C
authors.lastname: Toussaint
authors.forename: M
authors.initials: M
authors.lastname: Claus
authors.forename: E
authors.initials: E
authors.lastname: Fritschka
authors.forename: T
authors.initials: T
authors.lastname: Philipp
authors.forename: H
authors.initials: H
authors.lastname: Vetter
authors.forename: H
authors.initials: H
authors.lastname: Feltkamp
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007610:Kallikreins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors
chemical_list: D010919:Placebos; D007610:Kallikreins